Functional assessment of mobility imaging of stem cell therapy
Phone : +33 4 67 33 72 31
Email : firstname.lastname@example.org
The group members
JORGENSEN Christian (PU-PH)
BERNARD Laurene (CCA-AHU)
FISSOUN Christina (PhD student)
MAROUN Georges (PhD student)
RAKOTOZAFIARISON Antsa (MD)
Mesenchymal stromal cells
Mobility assessment to understand OA phenotype and develop new therapeutic approaches
Physiological ageing in the musculoskeletal system manifests as loss of muscle strength and muscle mass, known as sarcopenia and breakdown of the cartilage such as OA. Aging is associated with decrease in mobility related to alterations of the musculoskeletal system due to muscle atrophy and OA. In collaboration with UMR INSERM U1046, we will perform a complete phenotyping of muscle dysfunctions in OA patients (nutritional parameters, muscle and grip strength, muscle mass, whole body absorptiometry, inflammatory muscle and myokin biomarkers, physical activity and frailty). We will use the X-Sens kinematic assessment for gait and movement analysis. This allows calculating the spatiotemporal gait parameters and reconstructing the kinematic, kinetic and muscular patterns in real time and predict the performance outcome measures during motor and functional progresses. This will be translated into operational clinical guidelines for the healthcare multi-disciplinary team. These tools will allow to i) assess the impact of different physiological stimuli on joint mobility, ii) develop innovative rehabilitation strategies to restore mobility.
Multimodality imaging to stratify OA phenotype
Loaded and dynamic imaging are essential to integrate data with mobility modeling. Image improvements such as signal-to-noise ratio and spatial resolution gains, longer relaxation time, increased magnetic susceptibility effect and increased chemical displacement allow us to consider a functional analysis of cartilage. We will integrate and improve cartilage imaging. These improved imaging methods can be applied to detect subtle anatomical, functional and metabolic abnormalities associated with a wide range of joint disorders
Promote cell therapy development
To foster translational stem cell medicine, we will initiate new clinical trials using innovative biomaterials (cells and exosomes) within the first 5 years of the project. These clinical applications will benefit from aim 1-3 output. We will provide dedicated clinical space and trained physicians for the administration of these new biotherapies in the clinical center. The clinical teams have gathered a strong expertise in cell-based clinical trials through several phase 2-3 randomized double-blind trials on MSCs in knee OA (ADIPOA1 and ADIPOA2) and in DDD (RESPINE, MODI-PRP).